Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II Clinical Trial Evaluating Ipilimumab and Nivolumab in Combination for the Treatment of Rare Gastrointestinal, Neuro-Endocrine and Gynaecological Cancers

Next Previous
Trial Profile

A Phase II Clinical Trial Evaluating Ipilimumab and Nivolumab in Combination for the Treatment of Rare Gastrointestinal, Neuro-Endocrine and Gynaecological Cancers

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 05 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
  • Indications Biliary cancer; Bronchial cancer; Carcinoid tumour; Carcinoma; Cholangiocarcinoma; Clear cell sarcoma; Duodenal cancer; Gallbladder cancer; Gastrointestinal cancer; Gynaecological cancer; Intestinal cancer; Leiomyosarcoma; Neuroendocrine tumours; Ovarian cancer; Pancreatic cancer; Sarcoma; Squamous cell cancer; Uterine cancer
  • Focus Therapeutic Use

    • Most Recent Events

    • 12 Jun 2020 Results of subgroup analysis (n=29) of outcome of the neuroendocrine cohort of the CA209-538 clinical trial published in the Clinical Cancer Research
    • 31 May 2020 Results (n=41 ,advanced rare gynecological malignancies) presented at the 56th Annual Meeting of the American Society of Clinical Oncology.
    • 31 May 2020 Results (n=39, advanced biliary tract cancers), presented at the 56th Annual Meeting of the American Society of Clinical Oncology
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top